Drugs / MRT-8102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07119125 | Jun 2025 → Jul 2026 overdue | — | Monte Rosa Therapeutics, Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Monte Rosa Therapeutics, Inc | Results Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates monterosatx.com ↗
Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window |
| 2026-01-07 | Monte Rosa Therapeutics, Inc | Results Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects monterosatx.com ↗
After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Monte Rosa Therapeutics, Inc | Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates monterosatx.com ↗ |
| 2026-01-07 | Monte Rosa Therapeutics, Inc | Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects monterosatx.com ↗ |
| 2026-01-06 | Monte Rosa Therapeutics, Inc | Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results monterosatx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRT-8102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07119125 ↗ |
| Route | Oral | “when MRT-8102 is administered orally as single and multiple doses” NCT07119125 ↗ |